Black Diamond Therapeutics, Inc. Common Stock (BDTX)

Price$1.97

Value ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-56.10%

Price vs S&P 500 (4W)-26.65%

VGM Score57.84

Market Capitalization$112.88M

P/E Ratio (Annual)5.05x

All Metrics

P/CF (Annual)3.81x

Book Value / Share (Quarterly)$1.82

P/TBV (Annual)1.01x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.59

Price vs S&P 500 (YTD)-25.02%

EPS (TTM)$-0.76

10-Day Avg Trading Volume2.55M

EPS Excl Extra (TTM)$-0.76

EPS (Annual)$0.39

ROI (Annual)19.93%

Cash / Share (Quarterly)$2.06

P/E Basic Excl Extra (TTM)7.66x

P/E Normalized (Annual)5.05x

ROA (Last FY)15.64%

EBITD / Share (TTM)$-0.93

ROE (5Y Avg)-55.45%

Cash Flow / Share (Annual)$0.52

P/B Ratio1.08x

P/B Ratio (Quarterly)1.17x

Net Income / Employee (Annual)$1,065,100

Net Interest Coverage (TTM)-413.41x

ROA (TTM)-28.80%

EV / EBITDA (TTM)6.45x

EPS Incl Extra (Annual)$0.39

Current Ratio (Annual)8.42x

Quick Ratio (Quarterly)8.14x

3-Month Avg Trading Volume1.03M

52-Week Price Return-17.72%

EV / Free Cash Flow (Annual)2.80x

P/E Incl Extra (TTM)7.66x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.60

P/S Ratio (Annual)1.61x

Asset Turnover (Annual)0.49x

52-Week High$4.94

EPS Excl Extra (Annual)$0.39

Tangible BV CAGR (5Y)82.07%

26-Week Price Return-44.71%

Quick Ratio (Annual)8.18x

13-Week Price Return-15.04%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.46x

Enterprise Value$82.81M

Book Value / Share Growth (5Y)-25.45%

Revenue / Employee (Annual)$3,333,300

Pretax Margin (Annual)31.95%

Cash / Share (Annual)$2.25

3-Month Return Std Dev112.32%

Net Income / Employee (TTM)$-2,057,700

ROE (Last FY)19.93%

Net Interest Coverage (Annual)-12.43x

EPS Basic Excl Extra (Annual)$0.39

EV / Free Cash Flow (TTM)5.08x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.76

ROI (TTM)-36.37%

Revenue / Share (Annual)$1.22

Tangible BV / Share (Annual)$3.18

Forward P/E4.75x

Price vs S&P 500 (52W)-44.76%

P/E Ratio (TTM)7.66x

Year-to-Date Return-13.99%

5-Day Price Return-5.86%

EPS Normalized (Annual)$0.39

ROA (5Y Avg)-40.44%

Net Profit Margin (Annual)31.95%

Month-to-Date Return-5.86%

Cash Flow / Share (TTM)$-2.09

EBITD / Share (Annual)$0.22

Operating Margin (Annual)17.89%

P/CF (TTM)5.78x

ROI (5Y Avg)-55.45%

P/E Excl Extra (TTM)7.66x

EPS Basic Excl Extra (TTM)$-0.76

P/TBV (Quarterly)0.87x

P/B Ratio (Annual)1.23x

Book Value / Share (Annual)$1.96

Price vs S&P 500 (13W)-25.54%

Beta3.20x

P/FCF (Annual)3.81x

Revenue / Share (TTM)$0.00

ROE (TTM)-36.37%

52-Week Low$1.93

vGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.16est. -0.19

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.20

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BDTXBlack Diamond Therapeutics, Inc. Common Stock	A	—	D	$1.97
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Black Diamond Therapeutics is a clinical-stage oncology company developing small molecule therapies targeting specific cancer mutations across multiple tumor types. The company's proprietary Mutation-Allostery-Pharmacology platform identifies drug targets in families of oncogenic mutations, addressing a significant market opportunity in precision cancer medicine. Its pipeline includes two lead programs, BDTX-4933 and BDTX-1535.